SOMERSET, N.J.--(BUSINESS WIRE)--Jan. 2, 2024--
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco, CA. Ying Huang, Ph.D., the company’s chief executive officer, will deliver the company presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT.
The live audio webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website. The audio webcast replay will be available approximately 48-hrs after the webcast.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at https://legendbiotech.com/ and follow us on X (formerly Twitter) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102013797/en/
Investor:
Jessie Yeung, Head of Investor Relations & Public Relations, Legend Biotech
jessie.yeung@legendbiotech.com
Press:
Alexandra Ventura, Manager, Corporate Communications & Investor Relations, Legend Biotech
alex.ventura@legendbiotech.com
732-850-5598
Source: Legend Biotech Corporation
